Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott North

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 20, 2014
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologistsTina Hsu, Peter C Black, Kim N Chi, et al.
Cancers|November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint InhibitorsDaniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)Fred Saad, Kim N Chi, Antonio Finelli, et al.
Urology|March 13, 2010
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapyMichael M Vickers, Toni K Choueiri, Miranda Rogers, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 6, 2024
2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinomaCarlos E Stecca, Deepro Chowdhury, Normand Blais, et al.
Journal of Clinical Pharmacology|June 23, 2015
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancerKim N Chi, Jennifer Spratlin, Christian Kollmannsberger, et al.
Clinical Genitourinary Cancer|May 14, 2014
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient populationHusain K Khambati, Toni K Choueiri, Christian K Kollmannsberger, et al.
Clinical Genitourinary Cancer|May 3, 2014
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database ConsortiumLauren C Harshman, Nils Kroeger, Sun Young Rha, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 20, 2014
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologistsTina Hsu, Peter C Black, Kim N Chi, et al.
Cancers|November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint InhibitorsDaniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)Fred Saad, Kim N Chi, Antonio Finelli, et al.
Urology|March 13, 2010
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapyMichael M Vickers, Toni K Choueiri, Miranda Rogers, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 6, 2024
2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinomaCarlos E Stecca, Deepro Chowdhury, Normand Blais, et al.
Journal of Clinical Pharmacology|June 23, 2015
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancerKim N Chi, Jennifer Spratlin, Christian Kollmannsberger, et al.
Clinical Genitourinary Cancer|May 14, 2014
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient populationHusain K Khambati, Toni K Choueiri, Christian K Kollmannsberger, et al.
Clinical Genitourinary Cancer|May 3, 2014
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database ConsortiumLauren C Harshman, Nils Kroeger, Sun Young Rha, et al.
Pageof 10